BACKGROUND: Following a pneumocystis pneumonia (PCP) outbreak in our nephrology unit, all transplant patients were offered chemoprophylaxis with trimethoprim-sulphamethoxazole (TMP-SMX) as the first line agent. A high rate of complications was noted. We aimed to quantify TMP-SMX associated adverse events and evaluate its prophylactic benefit in their light. Potential risk factors for complications' development were also investigated. METHOD: This was an observational study of outcomes in transplant recipients commenced on TMP-SMX prophylaxis for 1year period. End-points were adverse events due to TMP-SMX, the additional medical burden resulting from these events, and PCP diagnosis. RESULTS: 290 patients commenced on TMP-SMX. 110 (38%) developed complications with most common being rise in serum creatinine (Cr) (n = 63, 22%) followed by gastrointestinal symptoms (n = 15, 5%), and leucopenia (n = 5, 2%). PCP incidence fell from 19 cases in 19 months to 2 cases in 12 months. Baseline renal function (P = 0.019) was an independent predictors for developing rise in Cr with TMP-SMX. CONCLUSION: Use of chemoprophylaxis is an effective strategy in dealing with a PCP outbreak but can lead to a high number of complications. Rises in serum Cr can cause significant concern and increase in the number of investigations.
BACKGROUND: Following a pneumocystis pneumonia (PCP) outbreak in our nephrology unit, all transplant patients were offered chemoprophylaxis with trimethoprim-sulphamethoxazole (TMP-SMX) as the first line agent. A high rate of complications was noted. We aimed to quantify TMP-SMX associated adverse events and evaluate its prophylactic benefit in their light. Potential risk factors for complications' development were also investigated. METHOD: This was an observational study of outcomes in transplant recipients commenced on TMP-SMX prophylaxis for 1year period. End-points were adverse events due to TMP-SMX, the additional medical burden resulting from these events, and PCP diagnosis. RESULTS: 290 patients commenced on TMP-SMX. 110 (38%) developed complications with most common being rise in serum creatinine (Cr) (n = 63, 22%) followed by gastrointestinal symptoms (n = 15, 5%), and leucopenia (n = 5, 2%). PCP incidence fell from 19 cases in 19 months to 2 cases in 12 months. Baseline renal function (P = 0.019) was an independent predictors for developing rise in Cr with TMP-SMX. CONCLUSION: Use of chemoprophylaxis is an effective strategy in dealing with a PCP outbreak but can lead to a high number of complications. Rises in serum Cr can cause significant concern and increase in the number of investigations.
Authors: Matthias Maruschke; Diana Riebold; Martha Charlotte Holtfreter; Martina Sombetzki; Steffen Mitzner; Micha Loebermann; Emil Christian Reisinger; Oliver W Hakenberg Journal: Wien Klin Wochenschr Date: 2014-09-19 Impact factor: 1.704
Authors: Charles D Varnell; Tsuyoshi Fukuda; Cassie L Kirby; Lisa J Martin; Barry L Warshaw; Hiren P Patel; Deepa H Chand; Gina-Marie Barletta; Scott K Van Why; Rene G VanDeVoorde; Donald J Weaver; Amy Wilson; Priya S Verghese; Alexander A Vinks; Larry A Greenbaum; Jens Goebel; David K Hooper Journal: Pediatr Transplant Date: 2017-09-04
Authors: Jonathan Ling; Tara Anderson; Sanchia Warren; Geoffrey Kirkland; Matthew Jose; Richard Yu; Steven Yew; Samantha Mcfadyen; Alison Graver; William Johnson; Lisa Jeffs Journal: Clin Kidney J Date: 2017-06-23
Authors: Su Hwan Lee; Kyu Ha Huh; Dong Jin Joo; Myoung Soo Kim; Soon Il Kim; Juhan Lee; Moo Suk Park; Young Sam Kim; Se Kyu Kim; Joon Chang; Yu Seun Kim; Song Yee Kim Journal: Sci Rep Date: 2017-05-08 Impact factor: 4.379
Authors: Tark Kim; Heungsup Sung; Yong Pil Chong; Sung Han Kim; Eun Ju Choo; Sang Ho Choi; Tae Hyong Kim; Jun Hee Woo; Yang Soo Kim; Sang Oh Lee Journal: Infect Chemother Date: 2018-06